11:59 AM EDT, 09/22/2022 (MT Newswires) -- Biomea Fusion (BMEA) said Thursday that new study data show that its drug BMF-219 is able to improve pancreatic beta cell area and function in two preclinical rat models of diabetes during the dosing period.
Both glycemic and lipemic control were maintained in the groups after the dosing period ended, according to the company.
The treatment led to a sustained increase in beta cell area and function in one of the rat models, compared with rats treated with vehicle or active control pioglitazone. BMF-219 also showed a recovery of beta-cell activity in the second rat model after 16 days of treatment, compared with rats treated with vehicle control or pioglitazone, Biomea said.
The treatment also showed an increase in beta cell mass in ex-vivo experiments with human donor islets, according to a statement.
The company said it is on track to file an investigational new drug application to explore the use of BMF-219 in type-2 diabetes in the second half of 2022.
Biomea shares were down 0.6% in recent trading.
Price: 10.99, Change: -0.17, Percent Change: -1.52